Role Summary
The Genesis Therapeutics MBA Internship Program is an immersive 12-week experience designed for ambitious MBA students seeking to make a mark in the biotech industry. This program offers the unique opportunity to engage in significant projects, providing direct exposure to the intricacies of financial planning and analysis within the biotech sector. Interns will work closely with industry professionals, gaining unparalleled insight and contributing to real-world financial solutions. Our program is designed not only to provide practical experience but also to identify and nurture talent for future full-time positions within our Finance team.
This internship is based in San Diego, CA. We offer flexible work arrangements, including in-office and hybrid options, to accommodate the diverse needs of our team.
Key Responsibilities
- Support critical Finance processes including budgeting, forecasting, business planning, and investment valuations.
- Participate in R&D project portfolio financial planning, including prioritization and risk analysis.
Program Highlights
- A full-time, paid internship lasting 12 weeks, starting in May or June 2024.
- Ownership of business-critical projects with real impact.
- Opportunities to work alongside and learn from leading professionals in the biotech industry.
Who You Are
- Currently enrolled in an MBA program with a strong interest in a career in finance in the biotech industry.
- A background in finance or life sciences is preferred, showcasing a blend of financial modeling, quantitative, and analytical skills.
- Exceptional communication abilities, capable of engaging effectively across all organizational levels.
- A collaborative team player with a proven track record of delivering results and a drive for excellence.
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry’s most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022, with a $20M upfront payment and a $670M total deal size), and Genentech (signed in 2020). We raised a $200M series B in August 2023, and have raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA’s VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Finding the best talent is our top priority at Genesis Therapeutics. If you are interested in potential partnership on recruitment, please reach out to [email protected]. 
